Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
342 | 3549 | 46.5 | 84% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
630 | 13104 | CYTOMEGALOVIRUS//HUMAN CYTOMEGALOVIRUS//HHV 6 |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | HUMAN CYTOMEGALOVIRUS | Author keyword | 118 | 37% | 7% | 256 |
2 | HCMV | Author keyword | 65 | 40% | 4% | 127 |
3 | US28 | Author keyword | 28 | 81% | 0% | 17 |
4 | ONCOMODULATION | Author keyword | 24 | 91% | 0% | 10 |
5 | GUINEA PIG CYTOMEGALOVIRUS | Author keyword | 22 | 81% | 0% | 13 |
6 | GLYCOPROTEIN B | Author keyword | 15 | 31% | 1% | 41 |
7 | RHESUS CYTOMEGALOVIRUS | Author keyword | 14 | 100% | 0% | 7 |
8 | CYTOMEGALOVIRUS VACCINE | Author keyword | 12 | 75% | 0% | 9 |
9 | GB GENOTYPES | Author keyword | 12 | 86% | 0% | 6 |
10 | KLIN MOL VIROL | Address | 10 | 22% | 1% | 41 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | HUMAN CYTOMEGALOVIRUS | 118 | 37% | 7% | 256 | Search HUMAN+CYTOMEGALOVIRUS | Search HUMAN+CYTOMEGALOVIRUS |
2 | HCMV | 65 | 40% | 4% | 127 | Search HCMV | Search HCMV |
3 | US28 | 28 | 81% | 0% | 17 | Search US28 | Search US28 |
4 | ONCOMODULATION | 24 | 91% | 0% | 10 | Search ONCOMODULATION | Search ONCOMODULATION |
5 | GUINEA PIG CYTOMEGALOVIRUS | 22 | 81% | 0% | 13 | Search GUINEA+PIG+CYTOMEGALOVIRUS | Search GUINEA+PIG+CYTOMEGALOVIRUS |
6 | GLYCOPROTEIN B | 15 | 31% | 1% | 41 | Search GLYCOPROTEIN+B | Search GLYCOPROTEIN+B |
7 | RHESUS CYTOMEGALOVIRUS | 14 | 100% | 0% | 7 | Search RHESUS+CYTOMEGALOVIRUS | Search RHESUS+CYTOMEGALOVIRUS |
8 | CYTOMEGALOVIRUS VACCINE | 12 | 75% | 0% | 9 | Search CYTOMEGALOVIRUS+VACCINE | Search CYTOMEGALOVIRUS+VACCINE |
9 | GB GENOTYPES | 12 | 86% | 0% | 6 | Search GB+GENOTYPES | Search GB+GENOTYPES |
10 | GLYCOPROTEIN N | 9 | 83% | 0% | 5 | Search GLYCOPROTEIN+N | Search GLYCOPROTEIN+N |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | EARLY REGION 2 GENE | 161 | 92% | 2% | 65 |
2 | IE86 PROTEIN | 127 | 92% | 1% | 49 |
3 | LOW MULTIPLICITY INFECTION | 125 | 94% | 1% | 45 |
4 | ENDOGENOUS HUMAN CYTOMEGALOVIRUS | 111 | 87% | 2% | 54 |
5 | MURINE CYTOMEGALOVIRUS | 110 | 35% | 7% | 254 |
6 | GP55 116 GB | 99 | 97% | 1% | 29 |
7 | IE2 86 KILODALTON PROTEIN | 93 | 100% | 1% | 28 |
8 | 86 KILODALTON PROTEIN | 90 | 96% | 1% | 27 |
9 | TRANSIENT COMPLEMENTATION | 84 | 71% | 2% | 68 |
10 | UL131 128 GENES | 81 | 87% | 1% | 40 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
The pathogenesis of human cytomegalovirus | 2015 | 8 | 80 | 43% |
The Story of Human Cytomegalovirus and Cancer: Increasing Evidence and Open Questions | 2009 | 75 | 87 | 78% |
The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies? | 2015 | 2 | 90 | 63% |
Cytomegalovirus and glioma: putting the cart before the horse | 2015 | 2 | 84 | 63% |
Immunobiology of Human Cytomegalovirus: from Bench to Bedside | 2009 | 163 | 277 | 29% |
ANALYSIS OF THE PROTEIN-CODING CONTENT OF THE SEQUENCE OF HUMAN CYTOMEGALOVIRUS STRAIN AD169 | 1990 | 979 | 160 | 52% |
Cytomegalovirus and brain tumor: epidemiology, biology and therapeutic aspects | 2013 | 17 | 39 | 72% |
Latency and reactivation of human cytomegalovirus | 2006 | 150 | 131 | 61% |
Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease | 2014 | 7 | 116 | 65% |
Cytomegalovirus cell tropism | 2008 | 100 | 86 | 66% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | KLIN MOL VIROL | 10 | 22% | 1.2% | 41 |
2 | HELEN C LEVITT VIRAL PATHOGENESIS DIS | 9 | 83% | 0.1% | 5 |
3 | ST ORSOLA GEN HOSP | 9 | 55% | 0.3% | 11 |
4 | MAX VON PETTENKOFER VIROL | 8 | 44% | 0.4% | 14 |
5 | VACCINE GENE THER Y | 7 | 13% | 1.4% | 48 |
6 | KAROLINSKA SYST BIOMED | 6 | 100% | 0.1% | 4 |
7 | MOL TUMOR VIROL | 5 | 19% | 0.6% | 23 |
8 | KLIN MOLEK VIROL | 4 | 67% | 0.1% | 4 |
9 | CLIN UNIT MICROBIOL | 4 | 56% | 0.1% | 5 |
10 | ZENTRUM HYG | 4 | 26% | 0.4% | 13 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000270284 | MURINE CYTOMEGALOVIRUS//MCMV//LY49H |
2 | 0.0000137310 | CONGENITAL INFECTION//CONGENITAL CYTOMEGALOVIRUS INFECTION//CYTOMEGALOVIRUS |
3 | 0.0000124977 | CMV SPECIFIC T CELLS//ONCOHEMATOL GRP//CYTOMEGALOVIRUS SPECIFIC T CELLS |
4 | 0.0000103137 | CYTOMEGALOVIRUS//VALGANCICLOVIR//GANCICLOVIR |
5 | 0.0000076322 | ICP8//UL9//ALKALINE NUCLEASE |
6 | 0.0000075080 | US3//VIRUS ASSEMBLY GRP//VIROL SHOWA KU |
7 | 0.0000064549 | IG LEVELS//LEUKEMIC CHILDREN//PROGNOSIS SURVIVAL |
8 | 0.0000061201 | C T USPHS//NULL CELLS//VIRUS THERMOSTABILITY |
9 | 0.0000052518 | CYTOMEGALOVIRUS COLITIS//CYTOMEGALOVIRUS ENTERITIS//CMV COLITIS |
10 | 0.0000048383 | MARJORIE B KOVLER VIRAL ONCOL S//ICP27//ICP0 |